Abstract
BackgroundAnti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those who...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have